ANN ARBOR, Ml / ACCESSWIRE / May 12, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. Management will also be conducting one-on-one meetings with investors.
Company Webcast
The Company's webcast presentation will be available for viewing at 9:00 am ET on Thursday, May 18, 2023. The presentation will be available to the public via webcast at: https://wsw.com/webcast/lytham8/zom/1899450.
Panel Presentation
Additionally, Mr. Heaton will be participating in a panel titled, "The State of Animal Health." This panel, also to be conducted virtually, will be held on Thursday, May 18, 2023, at 5:00 pm ET. To access the panel, please visit: https://wsw.com/webcast/lytham8/panel5/2275875.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register at https://www.lythampartners.com/spring2023invreg/.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
Follow Zomedica
| Last Trade: | US$0.04 |
| Daily Volume: | 735,048 |
May 13, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
